Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. (Q34620781)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Enrique de Alava

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Joan Maurel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ana Sofia Martins

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Andrés Poveda

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

José Antonio López-Guerrero

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ricardo Cubedo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Antonio Casado

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Javier Martínez-Trufero

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Juan Ramón Ayuso

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Antonio Lopez-Pousa

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Xabier Garcia-Albeniz

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Xavier Garcia del Muro

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

0 references

publication date

1 August 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

116

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

3692-3701

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20564079%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for analyzing interactions between biologically active agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

An evaluation of the cardiotoxicity of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25111

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34620781&oldid=1983967510"